• Bobcat339 in Reliable Epigenetic Assays

  2026-09-22

  A scenario-driven guide to using Bobcat339 (SKU BA4643) as a cytosine structure-based TET enzyme inhibitor in DNA methylation, viability, and osteogenesis workflows. It connects biochemical potency data with practical controls, storage requirements, interpretation limits, and vendor-selection considerations.

• Gastric Cancer Assembloids Model Tumor–Stroma Biology

  2026-09-22

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids by combining matched tumor organoids with stromal cell subpopulations from the same tumor. The model preserved clinically relevant epithelial–stromal interactions, altered transcriptional programs and drug responses, and provides a stronger platform for studying resistance and personalized treatment than tumor-only organoids.

• Tariquidar for Viscosity-Driven Chemoresistance

  2026-09-21

  Tariquidar (XR9576) provides a selective way to test whether mechanical stress promotes chemotherapy resistance through P-glycoprotein rather than through nonspecific toxicity. This workflow combines viscosity-controlled culture, transporter inhibition, efflux readouts, and mechanobiology markers to distinguish ABCB1-dependent resistance from parallel pathways.

• CUDC-907: Practical PI3K/HDAC Workflow

  2026-09-21

  CUDC-907 (SKU A4097) provides a single experimental reagent for examining coordinated PI3K/AKT signaling pathway inhibition and histone deacetylase (HDAC) inhibition in cell-based cancer research. This guidance covers formulation, starting conditions, quality control, and readouts; the material is for controlled scientific research only and should not be used for diagnosis, treatment, or clinical decisions.

• Bobcat339: TET Inhibition Workflow

  2026-09-20

  Bobcat339 enables mechanism-focused testing of TET1/TET2-dependent DNA demethylation alongside UHRF1, super-enhancer, and osteogenic pathways. This practical workflow links dose validation to DNA methylation, transcriptional, autophagy, and mesenchymal stem cell readouts without treating a chemical perturbation as a substitute for genetic evidence.

• Docetaxel Workflows for Chemoresistance Research

  2026-09-19

  Build more informative Taxotere experiments by connecting microtubule-driven mitotic arrest with apoptosis, cell-state profiling, and FOXM1-linked chemoresistance. This workflow shows how to optimize Docetaxel dosing, validate mechanism, and design combination studies without confusing cytostasis with cell death.

• O-GlcNAcylation Rewires Wnt-Driven Bone Formation

  2026-09-18

  The reference study identifies O-GlcNAcylation as a metabolic relay connecting Wnt3a stimulation to PDK1 stabilization, aerobic glycolysis, osteoblastogenesis, and bone repair. Its genetic, cellular, metabolic, and in vivo evidence provides a framework for studying Wnt signaling modulation while clarifying why pathway activation cannot be understood solely through transcriptional outputs.

• Dorsomorphin 2HCl: AMPK Workflow Guide

  2026-09-17

  Dorsomorphin 2HCl is an AMPK inhibitor for testing metabolic causality, with additional value in BMP, osteogenesis, and iron-regulatory models. This practical guide translates a probiotic–liver study into formulation, dosing, controls, and troubleshooting decisions for reproducible bench workflows.

• Bobcat339: TET Inhibition for DNA Methylation Studies

  2026-09-17

  Bobcat339 is a cytosine structure-based TET enzyme inhibitor for separating TET1/TET2-dependent DNA demethylation from broader methyltransferase effects. This practical guide connects biochemical screening, MSC osteogenesis assays, methylation profiling, and multi-omics validation while emphasizing dose selection and interpretation limits.

• Cucurbitacin I: A Precision STAT3 Perturbation Guide

  2026-09-16

  Cucurbitacin I, also known as JSI-124, provides a focused way to interrogate JAK2/STAT3 biology in cancer models. This guide combines pathway-level assay design with lessons from human SAN-plexus assembloids to improve mechanistic interpretation without overextending cross-domain evidence.

• Amphotericin B for Fungal Infection Research

  2026-09-16

  Build more informative fungal infection research workflows with Amphotericin B by separating direct membrane damage from biofilm-associated resistance and host-cell signaling. This guide connects dose-response testing, Candida albicans biofilm assays, PP2A–autophagy experiments, and troubleshooting into one practical framework.

• Docetaxel Resistance: From Microtubules to the Microbiome

  2026-09-15

  Docetaxel resistance is not only a problem of microtubule biology. Evidence linking gut dysbiosis, intratumoral lipopolysaccharide, and the NF-κB–IL6–STAT3 axis suggests a broader translational framework for studying Taxotere response. This article outlines how to connect molecular pharmacology, microbiome-aware models, and experimental strategy without overstating early evidence.

• Separating Growth Inhibition from Cell Death in Cancer Model

  2026-09-15

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a framework for distinguishing proliferative arrest from actual cell killing while accounting for differences in response magnitude and timing.

• LNP Surface Charge and V-ATPase Drive Delivery

  2026-09-14

  This 2026 study proposes that LNP tropism is determined by a synergy between nanoparticle surface charge and the V-ATPase activity of recipient cells. Its in vitro and in vivo experiments connect cellular endo/lysosomal state with charge-dependent delivery, offering a mechanistic framework for interpreting liver and lung targeting.

• GDC-0941: Reliable PI3K/Akt Assay Workflows

  2026-09-14

  This scenario-driven guide explains how GDC-0941 (SKU A8210) can improve the interpretation and reproducibility of PI3K/Akt pathway inhibition, viability, proliferation, and apoptosis workflows. It covers mechanism, solvent handling, protocol parameters, endpoint selection, and practical vendor evaluation for biomedical laboratories.

7919 records 1/528 page Next 12345 下5页 Last page